Adage Capital Partners Gp, L.L.C. Biocryst Pharmaceuticals Inc Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $8.69 Million - $19.7 Million	1,101,611 New	1,101,611 $11.7 Million
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $17.1 Million - $31 Million	-1,800,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$7.37 - $13.61 $1.47 Million - $2.72 Million	200,000 Added 12.5%	1,800,000 $18.3 Million
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $5.39 Million - $13.8 Million	1,600,000 New	1,600,000 $11.9 Million
Q2 2020 Aug 14, 2020	SELL	$1.9 - $5.61 $14.3 Million - $42.1 Million	-7,500,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $5.6 Million - $14.4 Million	3,500,000 Added 87.5%	7,500,000 $15 Million
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $6.36 Million - $13.8 Million	4,000,000 New	4,000,000 $13.8 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.